Prevention of Alopecia in Patients With Localised Breast Cancer (ICELAND)
Chemotherapy-induced Alopecia
About this trial
This is an interventional supportive care trial for Chemotherapy-induced Alopecia focused on measuring alopecia, chemotherapy-induced
Eligibility Criteria
Inclusion Criteria: Age >18 Female Histologically proven diagnosis of localised, non-metastatic breast cancer Indication for neo-adjuvant or adjuvant anthracycline and taxane chemotherapy (3 EC100 followed by 3 Docetaxel or 3 EC100 plus 12 Paclitaxel); HER-positive status is not a non-inclusion criterion. Patient willing to be photographed to assess IFA Fluency in French Patient affiliated to a social security scheme Signature of informed consent Exclusion Criteria: History of neck pain Pre-existing alopecia Participation in another trial Dermatosis of the scalp Contraindication to scalp cooling History of migraines, stroke or hyperthyroidism History of scalp metastases Sensitivity to cold, cold agglutinin disease, cryoglobulinaemia, cryofibrinogenaemia or post-traumatic cold dystrophy. Malignant haemopathies History of chemotherapy treatment Indication for cerebral irradiation Pregnant or breast-feeding patient Raynaud's syndrome
Sites / Locations
- centre François BaclesseRecruiting
- Centre Oscar Lambret
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
standard cold-cap
scalp-cooling technique
Patients will benefit from the prevention of chemo-induced alopecia using the standard cold cap device throughout the course of anthracycline- and taxane-based chemotherapy. This device will be supplemented by a compression bandage to add to the vasoconstriction action of the cold, the compression of the bandage on the scalp and thus optimise the effectiveness of the device.
Patients will benefit from the prevention of chemo-induced alopecia using the standard cold cap device throughout the course of anthracycline- and taxane-based chemotherapy.